What is the overall assessment of the Vyndamax controversy?
At $6.38 billion in 2025 revenue, tafamidis is about 10% of Pfizer's total — making every aspect of its franchise, from a list price ICER says needs an 85–95% cut, to patent settlements delaying generics to 2031, a high-stakes test of pharmaceutical accountability.
Vyndamax is financially crucial to Pfizer, earning $6.38 billion in 2025, about 10% of company revenue. The controversy is about everything around the molecule. On price, the trial's own investigator called the launch price gouging, the list price has risen from $225,000 to nearly $268,000, and ICER says it needs an 85% to 95% discount to be cost-effective. On access and public cost, patients have depended on copay assistance, and after the 2024 Medicare Part D changes cut most patients' costs to $0 per claim, Vyndamax claims rose 86%, with taxpayers bearing much of the bill; Medicare cannot negotiate the price because researchers classify tafamidis as a sole orphan drug. On competition, patent settlements delay generics to 2031, the discontinuation of Vyndaqel ahead of a 2028 patent expiry moved patients to a formulation protected to 2035, and rebate structures favour the incumbent. On promotion, Pfizer has been accused of misleading marketing claims, including over a disputed German ruling. Together they show how a company can maximise and prolong returns from a breakthrough drug, and why critics argue the rules should change. The key tests ahead are any antitrust review of the settlements and whether Congress narrows the orphan exemption.